Imagen de Portada

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuexue Zhou, Liang Zeng, Zhe Huang, Zhaohui Ruan, Huan Yan, Chun Zou, Shidong Xu, Yongchang Zhang
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Cancer Medicine
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
por: Wei‐Chun Chen, et al.
Publicado: (2024)

Stanniocalcin 2‐Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK /Beclin 1 Signaling
por: Yi‐Nan Liu, et al.
Publicado: (2026)

Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies
por: Fei Chen, et al.
Publicado: (2025)

The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
por: Rafik ElBeblawy, et al.
Publicado: (2025)

Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer
por: Zhe Huang, et al.
Publicado: (2025)

Beyond Chemotherapy: Network Meta‐Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer
por: Xinyu Li, et al.
Publicado: (2026)

Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
por: Yuxiang Sun, et al.
Publicado: (2026)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
por: Wentao Tian, et al.
Publicado: (2024)

The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
por: Fangfang Liu, et al.
Publicado: (2024)

Immunotherapy in Thyroid Cancer: Current Strategies and Challenges
por: Qian Zhang, et al.
Publicado: (2026)

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
por: Shuai Liang, et al.
Publicado: (2024)

Targeting Interleukin‐6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer
por: Akira Hattori, et al.
Publicado: (2025)

Long non‐coding RNA NEAT1 promotes aerobic glycolysis and progression of cervical cancer through WNT/β‐catenin/PDK1 axis
por: Min Su, et al.
Publicado: (2024)

Multi‐Transcriptomic Analysis Reveals That EREG ‐Driven TME Crosstalk Defines Anti‐ EGFR Response in Colorectal Cancer
por: Atsuki Taniguchi, et al.
Publicado: (2026)

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
por: Leah Lawrence
Publicado: (2026)

Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours
por: Martina Čarnogurská, et al.
Publicado: (2025)

SPARC Promotes Aerobic Glycolysis and 5‐Fluorouracil Resistance in Colorectal Cancer Through the STAT3/HK2 Axis
por: Jingrong Xiang, et al.
Publicado: (2025)

Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study
por: Ping‐Chih Hsu, et al.
Publicado: (2026)

Retraction: lncRNA ABHD11‐AS1 , regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2
Publicado: (2024)

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
por: Laura S. Puuniemi, et al.
Publicado: (2025)

YTHDF1 Regulates RELA m6A Modification and Activates the NF‐Kappa B Signaling Pathway to Promote the Mechanism of Gastric Cancer
por: Yangyuan Huang, et al.
Publicado: (2025)

Metal–Organic Frameworks Against Tumor Metastasis: Therapeutic Targets, Strategies, and Challenges for Clinical Translation
por: Jiahui Wang, et al.
Publicado: (2025)

An Integrated Clinical‐Radiomics‐Deep Learning Model Based on 18 F ‐ FDG PET / CT for Predicting EGFR Mutation Status in Lung Adenocarcinoma
por: Yun Wang, et al.
Publicado: (2025)

EGFR Mutation Detection in Whole Slide Images of Non‐Small Cell Lung Cancers Using a Two‐Stage Deep Transfer Learning Approach
por: Michele Zanoletti, et al.
Publicado: (2025)

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
por: Benjamin J. Lee, et al.
Publicado: (2024)

Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
por: Geoffrey Liu, et al.
Publicado: (2025)

Prognostic Implications of the Number of Lymph Node Metastases in Oral Tongue Squamous Cell Carcinoma: A Population Study of the SEER Database and an Institutional Registry
por: Wenjie Huang, et al.
Publicado: (2024)

phi and phiD predict adverse pathological features after radical prostatectomy for prostate cancer in Chinese population
por: Ruofan Shi, et al.
Publicado: (2024)

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR ‐ TKIs ( ML41256 ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
por: Wenfeng Fang, et al.
Publicado: (2025)

Lipid Metabolism in Gastrointestinal Malignancies: Exploring Dysregulation, Biomarkers, and Treatment Strategies
por: Yan An, et al.
Publicado: (2025)

Association of Germline Single Nucleotide Polymorphisms in Steroid Hormone Metabolism Pathway With Androgen Deprivation Therapy Prognosis of Prostate Cancer in Chinese Population
por: Ruofan Shi, et al.
Publicado: (2025)

Efficacy of Almonertinib Versus Osimertinib as the First‐Line Treatment for Non‐Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study
por: Xiujing Yao, et al.
Publicado: (2025)

Prognostic significance of glucose‐lipid metabolic index in pancreatic cancer patients with diabetes mellitus
por: Hailiang Wang, et al.
Publicado: (2024)

Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung Cancers
por: Jinjing Tan, et al.
Publicado: (2025)

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic
por: Ondrej Šušol, et al.
Publicado: (2024)

Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy
por: Steven Sun, et al.
Publicado: (2025)

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
por: Zhaohui Liao Arter, et al.
Publicado: (2025)

Nanoparticle‐Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy
por: Junrui Zhang, et al.
Publicado: (2025)

A Novel Strategy to Produce CAR ‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR /Cas9 and AAV
por: Ruoyu Dong, et al.
Publicado: (2026)

Can a nomogram predict apical prostate cancer pathology upgrade from fusion biopsy to final pathology? A multicenter study
por: Tianrui Feng, et al.
Publicado: (2024)